MolPharm xPharm- The Comprehensive Pharmacology Reference

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Nathanson, J. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Nathanson, J. A.

Phenyliminoimidazolidines. Characterization of a class of potent agonists of octopamine-sensitive adenylate cyclase and their use in understanding the pharmacology of octopamine receptors

JA Nathanson

Octopamine, a major aminergic neurotransmitter in invertebrates, exerts many of its actions through receptors which are associated with the activation of adenylate cyclase. The present study defines and characterizes a new class of potent octopamine agonists, the substituted phenyliminoimidazolidines (PIIs). Approximately 30 of these derivatives were examined for agonist and antagonist effects on the highly enriched and specific octopamine-sensitive adenylate cyclase present in the firefly light organ, as well as on adenylate cyclases present in other invertebrate and vertebrate tissues. Several derivatives were extremely active and some (e.g. 2,6-diethyl-PII) had potencies exceeding those of any previously described agonists of octopamine-sensitive adenylate cyclase. Stimulation by the potent PIIs was reversible, nonadditive to that caused by octopamine, and could be antagonized by antagonists such as cyproheptadine (Ki = 4 microM), phentolamine (Ki = 23 microM), and propranolol (Ki = 72 microM). These inhibitory constants agreed well with those for inhibiting octopamine stimulation. Certain PII derivatives acted as partial agonists and some as antagonists of octopamine stimulation. Structure-activity relationships revealed, among other things, that short-chain alkyl substitution in the 2- and 6-phenyl positions enhanced activity, as did further substitution of 4-halo, 4-methyl, or 4-hydroxy substituents. 4- Amino or N-alkyl substitution decreased activity. Structurally related benzylimidazoline derivatives such as tolazoline and naphazoline were partial octopamine agonists, generally less active than the PIIs. Comparison, in three invertebrate species, of the effects of the PIIs and two other chemical classes of octopamine agonists demonstrated clearcut differences in species responsiveness. Other comparative studies revealed that the agonist activity of the potent PIIs was specific for tissues containing an octopamine-sensitive adenylate cyclase; adenylate cyclases activated by dopamine or by beta 1- or beta 2-adrenergic agonists were unaffected by these compounds. Evaluation of the relative binding affinities of various PIIs for mammalian alpha- adrenergic receptors, as well as the ability of various antagonists to block PII binding, strongly suggested that the active PIIs are affecting a class of octopamine receptors distinct from mammalian alpha 1- or alpha 2-adrenergic receptors. These octopamine receptors also appeared distinct from mammalian 5-HT1 and 5-HT2 receptors. Correlative physiological studies in insects revealed that the active PIIs mimicked octopamine and were potent activators of light emission in the firefly light organ.(ABSTRACT TRUNCATED AT 400 WORDS)

Volume 28, Issue 3, pp. 254-268, 09/01/1985
Copyright © 1985 by American Society for Pharmacology and Experimental Therapeutics




This article has been cited by other articles:


Home page
J. Neurosci.Home page
P. A. Stevenson, V. Dyakonova, J. Rillich, and K. Schildberger
Octopamine and Experience-Dependent Modulation of Aggression in Crickets
J. Neurosci., February 9, 2005; 25(6): 1431 - 1441.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 1985 by the American Society for Pharmacology and Experimental Therapeutics